Naloxegol


Catalog No. size PriceQuantity
M6640-2S 2mg solid $85
M6640-10S 10mg solid $255

Description

Naloxegol, also known as and NKTR-118 and AZ-13337019, is a peripherally-selective opioid antagonist for the treatment of opioid-induced constipation. It was approved in 2014 in adult patients with chronic, non-cancer pain. Chemically, naloxegol is a pegylated (polyethylene glycol-modified) derivative of α-naloxol. Specifically, the 5-α-hydroxyl group of α-naloxol is connected via an ether linkage to the free hydroxyl group of a monomethoxy-terminated n=7 oligomer of PEG.

Product information

CAS Number: 854601-70-0

Molecular Weight: 651.78

Formula: C34H53NO11

Synonym:

NKTR-118

NKTR 118

NKTR118

AZ-13337019

AZ13337019

AZ 13337019

EGylated naloxol

Naloxegol Oxalate

trade names Movantik and Moventig

Chemical Name: (1S, 5R, 13R, 14S, 17S)-14-(2, 5, 8, 11, 14, 17, 20-heptaoxadocosan-22-yloxy)-4-(prop-2-en-1-yl)-12-oxa-4-azapentacyclo[9.6.1.0, .0, .0, ]octadeca-7, 9, 11(18)-triene-10, 17-diol

Smiles: COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5O[C@@H]1[C@]2(CCN3CC=C)C4=5

InChiKey: XNKCCCKFOQNXKV-ZRSCBOBOSA-N

InChi: InChI=1S/C34H53NO11/c1-3-9-35-10-8-33-30-26-4-5-27(36)31(30)46-32(33)28(6-7-34(33,37)29(35)25-26)45-24-23-44-22-21-43-20-19-42-18-17-41-16-15-40-14-13-39-12-11-38-2/h3-5,28-29,32,36-37H,1,6-25H2,2H3/t28-,29+,32-,33-,34+/m0/s1

Technical Data

Appearance: Solid Power.

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Soluble in DMSO, not in water.

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined.

HS Tariff Code: 382200

References:

  1. Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014 Jun 19;370(25):2387-96.
  2. Daniali M, Nikfar S, Abdollahi M. Evaluating naloxegol for the treatment of opioid-induced constipation. Expert Opin Pharmacother. 2020 Jun;21(8):883-891.

Products are for research use only. Not for human use.

Payment & Security

PayPal Venmo

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed